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Processes underlying the formation of dense core secretory
granules (DCGs) of neuroendocrine cells are poorly understood.
Here, we present evidence that DCG biogenesis is dependent on
the secretory protein secretogranin (Sg) II, amember of the gra-
nin family of pro-hormone cargo of DCGs in neuroendocrine
cells. Depletion of SgII expression in PC12 cells leads to a
decrease in both the number and size of DCGs and impairs DCG
trafficking of other regulated hormones. Expression of SgII
fusion proteins in a secretory-deficient PC12 variant rescues a
regulated secretory pathway. SgII-containing dense core vesi-
cles sharemorphological and physical properties with bona fide
DCGs, are competent for regulated exocytosis, and maintain
an acidic luminal pH through the V-type H-translocating
ATPase. The granulogenic activity of SgII requires a pH gradi-
ent along this secretory pathway. We conclude that SgII is a
critical factor for the regulation of DCG biogenesis in neuroen-
docrine cells, mediating the formation of functional DCGs via
its pH-dependent aggregation at the trans-Golgi network.
Derangements of catecholamine storage and release have
been widely implicated in human cardiovascular disease risk
(1, 2). Catecholamines are stored, together with peptides hor-
mones and neuropeptides, within large dense core secretory
granules (DCGs)4 in chromaffin cells andnoradrenergic nerves,
until prompted to undergo exocytotic release in response to
stimulation (3). The molecular mechanisms and regulatory
processes controlling the biogenesis of DCGs, and therefore
catecholamine storage and release, remain poorly understood.
The major soluble components of DCGs are the granin pro-
tein family of secreted pro-hormones (4), including chro-
mogranin A (CgA), chromogranin B (CgB), and secretogranin
(Sg) II. Because of their abundance and their capacity to aggre-
gate in vitrowithmatrix proteins and to interactwith the vesicle
membrane in environmental conditions found in the trans-
Golgi network (TGN) (e.g. presence of millimolar Ca2 and pH
5.5 (5–8)), granins have long been proposed to contribute to
some aspect of the formation of DCGs (9). In vitro and in vivo
evidence now suggests that CgA plays a critical role in the proc-
ess. Depletion of CgA in PC12 cells reduces the number of
DCGs (10–12) and the intracellular levels of other granule pro-
teins (12, 13). Impaired expression of CgA in transgenic mice
decreases the number of DCGs in the adrenal medulla and per-
turbs the storage and release of other DCG constituents,
including CgB, neuropeptide Y (NPY), and catecholamines (13,
14). Yet another CgA null mouse strain shows no phenotype
changes of DCGs in the adrenal medulla (15). However, the
observed substantial increase of CgB and SgII expression in
knock-out animals suggests that CgB and/or SgII might partly
compensate for CgA deficiency (15). Indeed, CgB depletion in
PC12 cells may contribute to an 80% decreased number of
DCGs (11), although CgB seems unable to rescue a regulated
secretory pathway in secretory-deficient neuroendocrine cells
(12, 16). A granulogenic role for CgA and CgB is also docu-
mented across cell lineages, where their expression induces the
formation of granule-like structures competent for exocytosis
(11, 12, 17–20).
The granin SgII is prominent within both human and rodent
secretory granules, including catecholamine storage vesicles
(21), but little is known about its granule forming activity in
neuroendocrine cells. Evidence gathered so far reports the for-
mation of granule-like structures in the fibroblast-like COS-1
cell line (19), and a vesicular distribution of secretoneurin
immunoreactivity in ischemic mouse muscle fibers (22). Com-
mon genetic variation at the human SCG2 locusmodulates SgII
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transcriptional expression, which correlates with blood pres-
sure elevation (2).Why are such quantitative alterations impor-
tant for systemic hypertension? If, like CgA, SgII plays a role in
the formation of catecholamine storage vesicles, then a mech-
anistic link between SgII variation and cardiovascular disease
would become plausible. Here, we provide a molecular defini-
tion of the DCG-forming function of SgII in neuroendocrine
cells by probing whether additive or subtractive changes in SgII
expression have consequences for DCG formation.
EXPERIMENTAL PROCEDURES
Construction of Expression Vectors—Expression plasmids for
GFP or a truncated form of embryonic alkaline phosphatase
(EAP) fused to the carboxyl terminus of full-length human SgII
(NM_003469), including its predicted 30-residue signal peptide
SIG (SgII-GFP and SgII-EAP), or to SgII signal peptide alone
(SIG-GFP and SIG-EAP) were described previously (23). A
cDNA encoding a monomeric form of RFP gene (gift from
Roger Tsien (24)) was amplified with specific primers incorpo-
rating a KpnI restriction site at the 3 end and aNotI restriction
site at the 5 end. The fragmentwas subcloned in-frame into the
same sites of pCMV-SgII-GFP to produce pCMV-SgII-RFP.
pCMV-SgII-EGFP served as a template to amplify full-length
SgII flanked by XhoI and KpnI restriction sites at the 5 and 3
ends, respectively. The amplified SgII fragment was subcloned
into the same sites of pCMV-CgA-HA (10) to produce pCMV-
SgII-HA. pCMV-SgII-HA was digested with NheI and NotI,
and the resulting fragment was cloned into the same sites of
pcDNA3.1/Hygro() (Invitrogen) to produce pcDNA-SgII-HA.
All plasmids were verified by restriction and DNA sequencing. A
vector encodingNPY fused toGFPwas a gift fromRichardMains
(pre-NPY-GFP (25)). A plasmid encoding botulinum C1 light
chain (pCDN3-BoNT/C1) was a gift from Robert Burgoyne (26).
Plasmids pECFP-Golgi and pECFP-C1 were purchased from
Clontech.
Cell Culture—Pheochromocytoma PC12 cells, the variant
sympathoadrenal cell line A35C (27), and the African green
monkey kidney fibroblast-derived COS-7 cells (ATCC, CRL
1651) were routinely grown as described previously (10, 20).
Most experiments were performed on cells plated onto either
poly-L-lysine (Sigma) plus collagen (Upstate)-coated 15-mm
round glass coverslips (Fischer No. 1) in 12-well Costar plates
or onto poly-L-lysine-coated 6- or 12-well plates.
The A35C-S7 clonal cell line that stably expresses SgII-HA
was obtained upon transfection of A35C cells with pcDNA-
SgII-HA followed by a selectionwith hygromycin B (800g/ml,
Invitrogen). Hygromycin B-resistant clones were screened
for SgII-HA expression by immunoblotting and immunofluo-
rescence microscopy. The A35C-S7 clone showed 80% of
cells expressing SgII-HA and was maintained in 500 g/ml
hygromycin B-containing medium until further experi-
ments. The corresponding control cell line, transfected with
the pcDNA3.1/Hygro() vector, was obtained and cultured
in the same conditions.
Transfection and siRNAGene Silencing—PC12 or A35C cells
were transfected with supercoiled plasmid DNA using
GenePorter 2 (gelatins) as described previously (28). COS-7
cells were transfected using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s protocol. SgII siRNA duplex
was designed with the siDESIGN algorithm (Dharmacon),
based on an AA(N19)TT pattern. The siDESIGN algorithm
(29) uses eight criteria to facilitate knockdown while minimiz-
ing off-target oligonucleotide effects. Sequences of the siRNA
oligonucleotides for rat SgII based on the reference mRNA
sequence accession number NM_022669 were as follows:
5-GAAGUUUCCUAGUCCAGAAdTdT-3 and antisense
5-UUCUGGACUAGGAAACUUCdTdT-3. BLAST of the rat
genome indicated that these oligonucleotide sequences were
unique to the intended SgII target. Previous studies have dem-
onstrated that even a single basemismatch is sufficient to abro-
gate the effect of an siRNA (30). Oligonucleotides were synthe-
sized and annealed by Sigma-Proligo. To further guard against
off-target oligonucleotide effects, the SilencerNegativeControl
1 siRNA (siRNA-Ct, Ambion), designed to have no significant
sequence similarity to mouse, rat, or human transcript se-
quences, was used as negative control in the transfections.
PC12 cells were transfected with 4g (12-well plate) of siRNA-
SgII or siRNA-Ct, using RNAiFect transfection reagent (Qia-
gen) at a 1:6 ratio. The culturemediumwas replaced 5–8 h after
the beginning of the transfection, and cells were further cul-
tured for 96 h.
Fluorescence Imaging and Immunocytochemistry—Trans-
fected PC12 and A35C cells were processed for deconvolution
fluorescence microscopy and immunocytochemistry as de-
scribed previously (23). Mitochondrial staining was achieved
using MitoTracker red CMXRos (Molecular Probes). For
immunocytochemistry, the primary antibodies were a rabbit
polyclonal anti-humanplacental alkaline phosphatase antibody
(1:50; Biomeda), a rabbit polyclonal anti-human SgII (1:250
(31)), a rabbit polyclonal anti-LGP110 (1:1000 (32)), a rabbit
polyclonal anti-EEA1 (1:100; BD Transduction Laboratories),
or a mouse monoclonal anti-HA antibody (1:1000; Covance).
Secondary antibodies were an Alexa Fluor 594-conjugated goat
anti-rabbit IgG (F(ab)2 at 1:250; Molecular Probes) or a fluo-
rescein-conjugated goat anti-mouse IgG (F(ab)2 at 1:350;
Biodesign International).
Images were captured on a DeltaVision deconvolution
microscopy system (Applied Precision) as described previously
(23). Briefly, optical xy sections along the z axis were acquired
with increments of 0.2mand deconvolved to generate optical
sections and three-dimensional images of the data sets. The
following excitation and emission wavelengths were used for
imaging: GFP and fluorescein-conjugated antibodies (green),
ex 490  10/em 528  38 nm; RFP, MitoTracker, and Alexa
Fluor 594 antibodies (red), ex 555 nm/em 580 nm; CFP (blue),
ex 436 10/em 465 30 nm; Hoechst 33342 (nuclear DNA
stain, blue), ex 350/em 461 nm. COS-7 cells were observed on
a Leica SP2 upright confocal laser scanning microscope
(DMRAX-UV) equippedwith the Acousto-Optical Beam Split-
ter system and with 25, 40, and 63 oil immersion objectives
(Leica, Microsystems, Reuil-Malmaison, France) as described
previously (20).
Quantification of Fluorescence Co-localization—The extent
of co-localization between fluorescence signals was analyzed as
described previously (23) using the pixel-per-pixel localization
algorithm of ImageMaster software (Photon Technology Inter-
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national), which uses Image-Pro as a backbone (Media Cyber-
netics). The averaged Pearson correlation coefficient (Rp) and
overlap coefficient (Ro) of each cell, quantitative of the degree of
overlap between two S1 and S2 fluorescent signals, were used
for statistical analysis of variance by Dunnett’s post test.
Electron Microscopy—Cells were processed for morphologi-
cal electron microscopy as described previously (10). For
immunogold labeling of SgII-HA in A35C-S7 cells, samples
were processed for ultrathin cryosectioning as described (33).
SgII-HAwas detected using amousemonoclonal anti-HA anti-
body (1:50; Covance) followed by a 10 nm gold-conjugated goat
anti-mouse secondary antibody (1:25; EY Laboratories). Images
were acquiredwith a JEOL 1200 EX II electronmicroscope, and
post-imaging analysis was performed using ImageJ. DCGs in
PC12 cells and electron-dense vesicular structures positive for
SgII-HA in A35C-S7 cells were circled and counted. The diam-
eter of each vesicle was calculated as the mean of the diameter
inferred from the perimeter and the diameter inferred from the
area of each drawn circle. 15 micrographs from PC12 cells and
34 micrographs of SgII-positive vesicular structures in
A35C-S7 cells were used for the analyses. The area of PC12
cytoplasm was calculated by measuring the area of the entire
cell minus the area occupied by the nucleus, and the density of
DCGs was calculated by dividing the number of granules by the
area of cytoplasm.
Measurement of Intravesicular pH—PC12 or A35C cells
grown on poly-L-lysine- and collagen-coated 25-mm round
glass coverslips (Warner Instruments) were transfected with
pCMV-SgII-EGFP and transferred into a perfusion chamber
(Quick Exchange, Warner Instruments). Monitoring of single
cell fluorescence was achieved with ImageMaster IM-2103-
6-HQ imaging system (Photon Technology International),
including a Nikon TS100 inverted microscope, a DeltaRAM
monochromator, and a CoolSnap HQ CCCD camera (Photo-
metrics). Filters used were a 505DRLP dichroic XF2010 and a
535AF45 emitter XF3084 (Omega Optical). Cells were incu-
bated in calcium saline buffer (CaB: 140 mMNaCl, 5.4 mM KCl,
0.8 mMMgCl2, 5 mM CaCl2, 10 mM glucose, 10 mMHEPES, pH
7.4) in which bafilomycin A1 (BafA1, LLC Laboratories) was
added to a 100 nM final concentration. At the end of each exper-
iment, algebraic conversion of GFP fluorescence to pH value
was obtained in situ by incubating the cells for 3 min in KCl-
rich media (125 mM KCl, 20 mM NaCl, 0.5 mM CaCl2, 0.5 mM
MgCl2, 5 Mmonensin, 5 M nigericin, 25 mM of MES or Tris)
buffered to pH values ranging from 4.5 to 8 (at a 0.5 pH unit
interval). For some KCl depolarization experiments, cells were
incubated in a buffer devoid of Ca2 (CaB: 140 mM NaCl, 5.4
mMKCl, 0.8mMMgCl2, 10mM glucose, 10mMHEPES, pH 7.4),
and the following reagents were superfused into the CaB or
CaB buffers: 50 mM KCl, 50 mM 1,2-bis-(o-aminophenoxy)-
ethane-N,N,N,N-tetraacetic acid, tetraacetoxymethyl ester,
cell permeant derivative (BAPTA/AM, Calbiochem).
Total Internal Reflection Fluorescence Microscopy (TIRFM)—
Cells expressing SgII-GFP were grown onto poly-L-lysine- and
collagen-coated 35-mm glass bottom culture dishes (MatTek)
and washed with serum-free DMEM prior to imaging per-
formed at room temperature on a custom system, including an
inverted Nikon TE300 fitted with a 60 high numerical aper-
ture objective lens (Nikon Plan Apo, N.A 1.45). Excitation was
produced by an argon/krypton ion laser (Melles Griott Multi-
line), and incident light for total internal reflection illumination
was introduced from the high numerical aperture objective
lenses. Images were acquired on an EMCCDCascade II camera
(Photometrics) controlled by Image-Pro Plus 5.0 software
(Media Cybernetics). The value of the penetration depth of the
evanescent wave used to excite GFP was estimated to be140
nm in the z axis after calibration using 2-m fluorescent poly-
mer microspheres. Exposure times were 100–200 ms, and
frames were acquired between 5 and 8 Hz in stacks of 200–600
images.
Analysis of Exocytosis by TIRFM—Time-sequence stacks of
images were manually inspected for rapid brightening of indi-
vidual spots using the public domain ImageJ software. Exocy-
totic fusion was defined as a sudden fluorescent burst into the z
plane followed by dispersal of the signal (34). The fluorescence
of each granule wasmeasured as the average intensity in a 1.2
1.2-m region of interest positioned over the center of the
granule using the time series analyzer plugin of ImageJ. Net
fluorescence intensity was obtained after subtracting the fluo-
rescence background measured outside the cell.
Single Vesicle Tracking and Diffusion Coefficient—Two-di-
mensional trajectories were obtained from 300-s time lapse
TIRFM images using the ImageJ Particle Detector and Tracker
plugin. The generated data set contained x and y coordinates as
a function of time. For each vesicle trajectory, the mean square
displacement (MSD) in the xy plane was calculated based on
mathematics described by Steyer and Almers (35) using a self-
made script for MATLAB software (The MathWorks). The
square displacement between two successive images during a
time interval twas defined by r2 (x(tt) x(t))2 (y(tt)
y(t))2. The diffusion coefficient Dxy was calculated as Dxy s/4,
with s being the slope of the linear fit of the MSD for a given
trajectory over a period of time .
Gel Electrophoresis and Immunoblotting—Total protein
lysates (20 g/well) or trichloroacetic acid-precipitated pro-
teins were prepared and immunoblotted as described previ-
ously (10). The primary antibodies usedwere as follows: a rabbit
polyclonal anti-human SgII (1:2000 in 5% nonfat drymilk (31));
a rabbit polyclonal anti-catestatin (1:500 in 5% nonfat dry milk
(36)); a goat polyclonal anti-CgB (C-19, 1:4000 in 5% FBS plus
0.1% Tween 20; Santa Cruz Biotechnology); a mouse mono-
clonal anti-actin (I-19, 1:500 in 5% FBS plus 0.1% Tween 20;
Santa Cruz Biotechnology); or a mouse monoclonal anti-HA
antibody (1:1000 in 5% FBS plus 0.1% Tween 20; Covance).
Horseradish peroxidase-conjugated secondary antibodies were
as follows: a goat anti-rabbit IgG (1:6000 in 5% nonfat dry milk;
Bio-Rad); a donkey anti-goat IgG (1:10,000 in 5% FBS plus 0.1%
Tween 20; SantaCruzBiotechnology); or a goat anti-mouse IgG
(1:7500 in 5% FBS plus 0.1% Tween 20; Biodesign Interna-
tional). Detection of horseradish peroxidase activity was
achieved by chemiluminescence (West Pico, Pierce). Quantita-
tive analysis of immunoreactivity was done with ImageJ
software.
Secretion Assay of EAP Chimeras—Cells transfected with the
expression plasmids encoding EAP fusion proteins were
washed twice with DMEM prior to 30 min of incubation in
Secretogranin II-mediated Granulogenesis
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DMEM supplemented or not with A23187. Cell culture super-
natants were collected, and cell lysates were prepared by quick
freeze/thaw in saline buffer (150 mM NaCl, 5 mM KCl, 2 mM
CaCl2, 10 mM HEPES, pH 7.4) containing 0.1% Triton X-100.
Detection of EAP enzymatic activity in supernatants and cell
lysates was achieved with a high sensitivity chemiluminescence
assay (Phospha-Light, Applied Biosystems). The secretion rate
of EAP chimeras was calculated as a percentage of the total EAP
activity present in the cells before stimulation. Total EAP activ-
ity is the sum of the amount released plus the amount remain-
ing in the cells.
Secretion Assay of SgII-HA—A35C-S7 cells stably expressing
SgII-HA were extensively washed with DMEM and incubated
in DMEM alone for 30min. Supernatants were collected, and
cells were further incubated in DMEM supplemented with
60 mM KCl, 1 M A23187, or 60 M nicotine (Sigma) for 30
min prior to final collection of supernatants. Supernatants
were cleared by centrifugation (10 min, 4000  g) and con-
centrated by trichloroacetic acid
precipitation. Pellets were pro-
cessed for gel electrophoresis and
immunoblotting.
Sucrose Gradient Fractionation—
A postnuclear supernatant from
homogenized cells was prepared
and subjected to sucrose density
gradient fractionation (0.6–2.2 M)
as described previously (37). Frac-
tions were collected and assayed for
sucrose concentration by refrac-
tometry and immunoblotted forHA
andCgB immunoreactivity after tri-
chloroacetic acid precipitation.
RESULTS
Down-regulation of SgII Expres-
sion by siRNA in PC12 Cells—We
designed an siRNA duplex (siRNA-
SgII) that specifically targets rat SgII
mRNA. Transfection of PC12 cells
with siRNA-SgII resulted in a80%
decrease of SgII protein expression
as compared with transfection with
a control siRNA (siRNA-Ct; Fig. 1,A
andB). Decreasing the expression of
CgA or CgB in cella or in vivo may
influence the expression of other
endogenous granins, including SgII
(11, 15, 38). Here we found that SgII
silencing does not interfere with the
expression of CgA or CgB when
compared with siRNA-Ct-treated
cells (Fig. 1, A and B).
Down-regulation of SgII Expres-
sion Alters Formation of DCGs in
PC12 Cells—Morphometric analy-
ses of DCGs in siRNA-SgII-treated
cells versus siRNA-Ct-treated PC12
cells were performed at the ultrastructural level by transmis-
sion electron microscopy (Fig. 1C; visual output not shown).
The number of DCG/m2 of cytoplasm was 0.72  0.09 in
siRNA-Ct-treated PC12 cells (Fig. 1C), consistent with DCG
abundance in naive PC12 cells (37). In contrast, the number of
DCGs was diminished by 44% (to 0.40  0.04 DCG/m2) in
response to 75% reduction of SgII expression (Fig. 1C).
Although 97% of DCGs were within a 85–195 nm diameter
range in both siRNA-Ct- and siRNA-SgII-treated PC12 cells,
the size distribution was shifted to lower values in SgII-silenced
PC12 cells (Fig. 1D; p	 0.001,Mann-Whitney test), resulting in
an average diameter of DCGs in siRNA-SgII-treated PC12 cells
significantly smaller (131.1  1.2 nm, n  572 granules) than
that of control cells (138.9 1.1 nm, n 586 granules). These
data reveal a significant contribution of SgII to the formation of
DCGs in sympathoadrenal PC12 cells, wherein a reduction in
SgII results in a significant decrease in both number and size of
DCGs.
FIGURE1.Depletionandalteredsecretorygranulemorphology in response tosiRNA-mediatedsilencing
of SgII in wild-type sympathoadrenal PC12 cells. A, granins expression. Representative immunoblot of
granins expression after siRNA silencing of SgII. Cell lysates from PC12 cells transfectedwith either siRNA-Ct or
siRNA-SgII (96 h) were subjected to immunoblot detection of SgII, CgB, and CgA expression. Actin served as a
normalization control. B, quantification of relative granin expression. The normalized SgII, CgB, and CgA
expression in siRNA-Ct-treated cells was considered to be 100%. Values are given as themean relative protein
expression of seven independent experiments S.E. †, p 0.05; ***, p	 0.001, t test. C and D, ultrastructural
analysesof dense coregranules after siRNAsilencingof SgII.Micrographs fromPC12cells treatedwith siRNA-Ct
or siRNA-SgII were analyzed for number of dense core granules per m2 of cytoplasm (C) and diameter (nm)
(D). n 187 (siRNA-Ct) and 127 (siRNA-SgII) cell planes. C, immunoblot inset represents SgII expression before
sample processing, quantified as described in B. ***, p 	 0.001, Kruskal-Wallis test. D, dense core granule
diameters were calculated from 572 (siRNA-Ct) and 586 (siRNA-SgII) randomly selected dense core granules.
Values were ranked according to interval, and the distribution of the resulting populations was compared
using a Kruskal-Wallis test.
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Reduction of SgII Expression Impairs Regulated Secretory
Peptide Trafficking into DCGs—The 36-amino acid peptide
neurotransmitter NPY is stored in DCGs of neuroendocrine
cells (25, 39–41). As expected, transient expression of NPY
fused to GFP (NPY-GFP (40)) in PC12 cells resulted in the
punctate distribution of the photoprotein in85% of the trans-
fected cells (Fig. 2B) that substantially co-localized with endog-
enous SgII (Pearson coefficient Rp 0.36 0.02, overlap coef-
ficient Ro 0.37 0.02, n 150 optical sections; Fig. 2A). This
partial rather than absolute co-localization was consistent with
previous reports localizing GFP fusion proteins (SgII-GFP (23)
and pro-ANF-GFP (28, 40)) with endogenous markers of
DCGs. Two other patterns of distribution of NPY-GFP were
observed as follows: (i) a patchy distribution that substantially
co-localized with the mitochondrion-selective probe Mito-
Tracker Red CMXRos (13.8% of
transfected cells; Rp  0.59  0.03;
Ro  0.5  0.04, n  181 optical
sections; Fig. 2, A and B), likely
resulting from the use of an alterna-
tive/internal translation initiation
(AUG) site reported to function in
mitochondrial targeting of NPY in
non-neuroendocrine or secretory-
deficient neuroendocrine cells
(42–45); and (ii) a juxtanuclear
distribution, co-localizing with
the TGN-resident glycoprotein
-1,4 galactosyltransferase (GalT-
CFP) (1.2% of transfected cells;
Rp 0.67 0.03; Ro 0.67 0.03;
8 cells, n  124 optical sections;
Fig. 2, A and B), reflecting the
incomplete sorting of NPY-GFP at
the TGN (37).
Silencing expression of SgII by
85% markedly altered NPY-GFP
targeting to chromaffin DCGs, re-
sulting in only 33.6% of the siRNA-
SgII-treated cells showing a vesicu-
lar distribution of fluorescence (an
2.5-fold decrease as compared
with control cells; Fig. 2B). More-
over, localization of NPY-GFP to
mitochondria was increased by
2.7-fold (37.4% of transfected
cells; Fig. 2B), although its accumu-
lation within the Golgi compart-
ment was increased by 24-fold
(29% of transfected cells; Fig. 2B).
Thus, SgII silencing results in the
redistribution of NPY-GFP from
DCGs to Golgi and mitochondrial
compartments, thereby providing
evidence of a contribution of SgII to
the formation of a regulated secre-
tory pathway.
SgII Induces the Formation of
Vesicular Structures in Neurosecretion-deficient A35C Cells—
Consistent with the granulogenic activity of an SgII-Myc fusion
protein in several non-neuroendocrine cell types (19), the tran-
sient expression of SgII-GFP in COS-7 cells drove the forma-
tion of discrete fluorescent punctae (supplemental Fig. S1, B
andD), although expression of the constitutively secreted SIG-
GFP (SgII signal peptide SIG fused to GFP (23)) did not
(supplemental Fig. S1A). Therefore, we used our series of SgII
fusion proteins (23) SgII-GFP, SgII-RFP (SgII fused to mono-
meric RFP), SgII-EAP (SgII fused to EAP) or SgII-HA to char-
acterize the granulogenic activity of SgII in a mutant neuroen-
docrine cell line. The PC12 cell variant A35C lacks DCGs and a
regulated secretory pathway and does not express several DCG
proteins, including SgII (10, 46). When expressed in A35C, the
constitutively secreted proteins SIG-GFP and SIG-EAP (23)
FIGURE 2. SgII is required for the correct trafficking of NPY-GFP into secretory granules. A and B, effect of
SgII silencingon secretory granule targetingofNPY in PC12 cells. PC12 cells treatedwith siRNA-Ct or siRNA-SgII
(96 h) were transfected with a plasmid encoding NPY-GFP for 24 h and analyzed by three-dimensional decon-
volutionmicroscopy after processing for photoprotein fluorescence and immunocytochemistry. A, represent-
ative optical xy sections of the three archetypal distributions of NPY-GFP observed in PC12 cells. MitoTracker
RedCMXros,GalT-CFP, andendogenousSgIIwereusedasmarkersofmitochondrial, Golgi, orDCGdistribution,
respectively. Scale bar,5m.B, relative subcellular distributionofNPY-GFP in control or silencedPC12cells. The
pattern of NPY-GFP localization in transfected cells (n  87, siRNA-Ct; n  107, siRNA-SgII) was classified
according to A. Values are expressed as a percentage of the number of analyzed cells. p 	 0.0001, row by
column contingency table (2  58.7, 2 degrees of freedom). C and D, expression of SgII reroutes NPY from
tubular to vesicular organelles inA35Ccells. A35Ccells transiently transfected (48h)with theplasmidencoding
NPY-GFP, alone or together with a plasmid encoding SgII-RFP, were processed for photoprotein fluorescence
and three-dimensional deconvolution microscopy. C, representative three-dimensional (3D) views of 9–13
optical xy sections acquired along the z axis. MitoTracker Red CMXros was used as a marker of the mitochon-
drial network. Nuclei (blue) were visualized with Hoechst 33342. Scale bars, 5 m. Co-localization (yellow) of
NPY-GFP (green) with eithermitochondria or SgII-RFP photoprotein (red) is shown in themerged images. Quan-
tification of fluorescence overlap is reported in the text. D, enlarged insets from C emphasize the punctate
co-localization of NPY-GFP in presence of SgII-RFP (inset 1) as opposed to the mitochondrial distribution of
NPY-GFP in absence of SgII-RFP signal (inset 2).
Secretogranin II-mediated Granulogenesis
10034 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285•NUMBER 13•MARCH 26, 2010
accumulated within the Golgi complex (Fig. 3A), typical behav-
ior of constitutively secreted proteins in sympathoadrenal cells,
includingA35C cells (supplemental Fig. S2A) (10, 23, 28, 37). In
sharp contrast, SgII-GFP, SgII-EAP, or SgII-HA displayed a
highly punctate distribution throughout the cell body (Fig. 3A)
and along the entire length and at the termini of neurite-type
processes in a subset of A35C cells (Fig. 3B). Such a distribution
pattern was largely similar to that observed in wild-type PC12
(supplemental Fig. S2A) (23) or primary chromaffin cells (23),
suggesting storage of the SgII fusion proteins in vesicular
organelles with typical DCG trafficking behavior. Turnover of
proteins from the constitutive secretory pathway is expected to
be rapid because of uninterrupted release, whereas proteins of
the regulated secretory pathway are stored and retained for
extended periods of time before release (18, 47). PC12 cells
expressing the regulated secretory chimera SgII-GFP (23) were
exposed to the protein synthesis inhibitor cycloheximide for 3 h
to prevent accumulation of newly synthesized proteins (18, 47,
48). In such cells, the punctate distribution of SgII-GFP
remained unaffected (supplemental Fig. S2B), consistent with
storage in DCGs (23). Similarly, a 3-h cycloheximide treatment
of A35C cells expressing SgII-RFP did not reduce the punctate
distribution of the chimera (Fig. 3C), effectively ruling out a
potential localization of SgII-RFP in constitutive secretory ves-
icles and suggesting efficient retention of SgII-RFP within
DCG-like structures. In contrast, Golgi accumulation of the
constitutively secreted SIG-GFP (23) in both PC12 and A35C
cells (supplemental Fig. S2A and Fig. 3A) completely disap-
peared after 3 h of cycloheximide treatment (data not shown),
consistent with a secretion rate being closely linked to the bio-
synthesis rate. When A35C cells stably expressing SgII-HA
(clonal cell line A35C-S7, see “Experimental Procedures”) were
next immunostained for the lysosomal/endosomal markers
LGP110 and EEA1 (32, 49), there was no co-localization with
SgII (Fig. 3D), a result observed aswell in transiently transfected
COS-7 cells (supplemental Fig. S1C). Thus, the vesicular struc-
tures formedupon adventitious expression of SgII inA35C cells
exhibit DCG properties and may not result from storage of the
graninwithin lysosomal/endosomal structures or routing of the
protein to the constitutive pathway.
Establishment of a Regulated Secretory Activity and Exocy-
totic Fusion in A35C Cells—We next tested the competence of
SgII-containing vesicles for regulated exocytosis, using the EAP
reporter as a highly sensitive way to quantify exocytotic release
by chemiluminescence (supplemental Fig. S2C) (23, 37, 50). In
COS-7 cells, the release of the constitutive secretory protein
SIG-EAP was elevated in basal, nonstimulating conditions
(7.8  0.6%; Fig. 4A, left) and only slightly augmented to 0.6-
fold over basal in response to the calcium ionophore A23187 (1
M, 30min; Fig. 4A, right). In contrast, nonstimulated secretion
of SgII-EAP was low (1.5%; Fig. 4A, left), suggesting the effi-
cient retention of the fusion protein. Moreover, A23187 trig-
gered 6.2  0.9% secretion of SgII-EAP into the extracellular
medium (4.2-fold increase over basal, p	 0.001; Fig. 4A, right).
In the neurosecretory-deficient A35C cells, the secretagogue
A23187 (5M, 30min) triggered release of SgII-EAP by 6.9-fold
over basal conditions (mock medium; p 	 0.001; Fig. 4B),
clearly demonstrating regulated secretion of the chimera. The
FIGURE 3. Subcellular distribution of SgII fusion proteins expressed in neu-
rosecretion-deficientsympathoadrenalA35Ccells.A35Ccells transfected (48
h) with expression plasmids encoding the indicated fusion proteins were pro-
cessed for photoprotein fluorescence or immunocytochemistry and three-di-
mensional deconvolution microscopy. Shown are the three-dimensional views
of 9–13 optical xy sections acquired along the z axis. Nuclei were visualizedwith
Hoechst 33342 (blue). SIG-EAP, SgII-EAP (red), and SgII-HA (green) chimera were
detected using the appropriate anti-reporter antibodies. Scale bars, 5m. A, cell
bodies. B, neurites. Substantial accumulation of SgII-HA/GFP/EAP chimeric pro-
teins is seen at the end of neurite-like structures, as exemplified in the enlarged
insetsof thedeconvolved images.C,A35C cells expressing SgII-RFPwere treated
(3 h) with a mock buffer (DMSO;CHX) or the protein synthesis inhibitor cyclo-
heximide (CHX) (10 g/ml;CHX) prior to processing for photoprotein fluores-
cence. D, A35C-S7 cells (stably expressing SgII-HA) were co-stained for SgII-HA
(green) and the lysosomal/late endosomal marker LGP110 or the early endo-
somal marker EEA1 (red). Absence of co-localization between SgII-HA and lyso-
somal or endosomal structures is exemplified in the enlarged insets from the
merged three-dimensional images.
Secretogranin II-mediated Granulogenesis
MARCH 26, 2010•VOLUME 285•NUMBER 13 JOURNAL OF BIOLOGICAL CHEMISTRY 10035
release of SgII-EAP was lower than that typically observed in
PC12 cells (supplemental Fig. S2C) (23) but significantly higher
than the release of SIG-EAP, which showed no response to
A23187 (p 0.05; Fig. 4B).
Additional insight into the regulated secretory profile of SgII
was obtained from the clonal cell line A35C-S7 (stably express-
ing SgII-HA, see “Experimental Procedures”). As expected,
exposure of A35C-S7 cells to A23187 (1M, 30min) stimulated
release of SgII immunoreactivity (5.9 1.2-fold over basal, p	
0.001; Fig. 4C). In addition, membrane depolarization (by 60
mM KCl) or stimulation of the physiological (nicotinic-cholin-
ergic) secretory pathway by nicotine (60 M) triggered signifi-
cant release of SgII immunoreactivity in the extracellularmilieu
by 4.8  0.8- and 4.9  1.7-fold over basal, respectively (p 	
0.001; Fig. 4C). Thus, release of SgII from A335C cells may be
triggered not only by creating artificial Ca2 pores but also by
secretagogues known to selectively activate cell surface Ca2
channels in neurosecretory cells.
We further examined the exocytotic fusion behavior of single
vesicles containing SgII-GFP in A35C cells by TIRFM, which
takes advantage of a laser-induced evanescent wave to selec-
tively excite fluorophores in the region adjacent to the glass
interface (34). Consistent with wide field fluorescence micros-
copy results (Fig. 3), we observed a pool of SgII-GFP-containing
vesicles within 140 nm of the plasma membrane of trans-
fected A35C (Fig. 4D). Exposure to A23187 (1 M) caused a
FIGURE4.Secretagogue-stimulatedexocytosisof SgII inCOS-7andA35Ccells.AandB, regulated secretionof EAP fusionproteins. COS-7 cells (A) andA35C
cells (B) expressing SIG-EAP or SgII-EAPwere exposed for 30min to DMEM alone () or DMEM supplementedwith the indicated concentration of A23187 ().
EAP type secretion was assayed as described under “Experimental Procedures.” Release of EAP is expressed either as % of EAP activity secretion (A, left) or
relative to enzymatic activity released in the absence of secretagogue (A, right, and B). Values are given as themean S.E. of triplicate determinations. Results
from one of at least three independent experiments are shown. †, p  0.05; ***, p 	 0.001, as compared with control, analysis of variance with Dunnett’s
post-hoc test.C, stimulated release of SgII-HA fromA35C-S7 cells. A35C-S7 cellswere sequentially exposed for 30min toDMEM () and thenDMEMcontaining
the indicated secretagogues (). The resulting supernatants were subjected to immunoblotting. The amount of secreted SgII-HA was quantified by densi-
tometry in three independent secretion experiments. The means S.E. of fold increases in stimulated () over basal () conditions were as follows: A23187,
5.9 1.2; KCl, 4.8 0.8; nicotine, 4.9 1.7.D, TIRFM image of a characteristic A35C cell expressing SgII-GFP. Only the pool of vesicleswithin140 nm from the
plasma membrane in the z axis (corresponding to the estimated penetration depth of the evanescent wave used to excite GFP) is seen. Scale bar, 5 m.
E, secretagogue-evoked release of SgII-GFP observed by TIRFM. The arrow in the overall view of a transfected A35C cell prior (1 s) to stimulation with 1 m
A23187 (left) indicates the exocytotic event depicted in the adjacent sequential images. Shown on the right is the quantification of the fluorescence intensity
changes measured from the sequential images.
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fluorescent burst into the z plane from a few discrete vesicles at
the plasma membrane, followed by a rapid dispersal of the sig-
nal within 500 ms (Fig. 4E). This behavior, although observed
less frequently than in PC12 cells, is characteristic of an exocy-
totic event (34) releasing SgII-GFP from the vesicle core, caus-
ing granular deprotonation and dequenching of the fluores-
cence of GFP as the fusion pore expands into the plasma
membrane. Taken together, these results clearly demonstrate
that the expression of SgII in neurosecretion-deficient A35C
re-induces a regulated secretory activity in the cells.
SgII Reroutes NPY Trafficking fromMitochondrial Compart-
ments into Secretory Granules in A35C Cells—When expressed
in A35C cells, NPY-GFP consistently displayed a branched,
reticular distribution that co-localized with MitoTracker Red
CMXRos (Rp 0.76 0.03 and Ro 0.77 0.03; Fig. 2, C and
D, inset 2), consistent with previous studies documentingmito-
chondrial targeting of NPY in secretory-deficient neuroendo-
crine cells (42–45). In sharp contrast, A35C cells co-expressing
NPY-GFP and SgII-RFP consistently showed a highly punctate
distribution and substantial co-localization of the two fluores-
cent signals (Rp  0.61  0.04 and Ro  0.61  0.04; Fig. 2, C
and D, inset 1). Thus, the expression of SgII in A35C cells res-
cues the trafficking of NPY into SgII-containing DCGs.
Morphology and Physical Properties of SgII-containing Vesi-
cles in A35C Cells Reveal Metrics Similar to Those of Genuine
DCGs—The morphology of the vesicular structures formed
upon SgII expression was first assessed by fluorescencemicros-
copy (Fig. 3A). In SgII-GFP-expressing A35C cells, the average
apparent diameter of fluorescent punctae was 290  1.2 nm,
similar to the 310  2.5 nm diameter of SgII-GFP-labeled
DCGs in normal PC12 cells (23). Examination by immunoelec-
tron microscopy of A35C-S7 cells revealed electron dense,
membrane-bound vesicles (Fig. 5A) with an average diameter
(133.2  6.8 nm) within the same range as that of chromaffin
DCGs (138.9 1.1 nm, Fig. 1D) (53). The resolution of fluores-
cence puncta is diffraction-limited, and ourmeasure of granule
diameter by light microscopy is, as expected, an overestimation
of the actual size of the granules that is more accurately esti-
mated by electron microscopy. We note that our estimation of
DCG size by fluorescence microscopy is consistent with earlier
reports from us and others estimating the diameter of fluoro-
phore-labeled DCGs (23, 51, 52, 54). Accumulation of SgII
within the dense core area of the granules was confirmed by the
presence ofHA-labeling 10 nmgold particles (Fig. 5A). No such
structures could be found in either naive A35C cells (10, 27) or
A35C cells stably transfected with the corresponding control
plasmid (pcDNA3.1/Hygro() vector; data not shown).
We next performed equilibrium sucrose density gradient
fractionation on post-nuclear supernatants prepared from a
sample combining both A35C-S7 and PC12 cells (Fig. 5, B and
C). Immunoreactivity for HA was used to identify A35C vesi-
cles, whereas endogenous CgB immunoreactivity specifically
localized PC12 DCGs along the gradient. SgII-HA co-localized
with CgB in the same fractions, with maximum immunoreac-
tivity at 1.24 M sucrose (Fig. 5C), consistent with the known
buoyant density of DCGs isolated from PC12 cells (28, 37).
Thus, expressing SgII in A35C cells results in the formation of
dense core vesicles with morphological and physical properties
largely similar to that of bona fide DCGs.
Dynamics of Single SgII-containing Vesicles in Living A35C
Cells—Wenext compared themobility of SgII-GFP-containing
granules between A35C and PC12 cells in resting conditions
(Fig. 6). The MSD from 150 SgII-containing vesicles in each
cell type (see “Experimental Procedures”) was determined from
tracking analyses (Fig. 6, A and B). When plotted against time
(Fig. 6C), MSDs from A35C and PC12 cells exhibited a linear
distribution, characteristic of random diffusion of the vesicles.
The distribution pattern of the diffusion coefficients was virtu-
ally identical between the two cell types (p 0.05,Mann-Whit-
ney test; Fig. 6D), with more than 82% of the vesicles within the
5–45104 m2s1 Dxy range, indicating similar motion of
SgII-containing granules in resting A35C and PC12 cells.
Acidic Environment Is a Prerequisite for the Secretory Gran-
ule Forming Activity of SgII in A35C Cells—We previously
reported the requirement of a pH gradient along the secretory
FIGURE 5.Morphometric analyses of SgII-containingdense coregranules
in A35C cells. A, immunoelectron microscopy analysis of A35C-S7 cell line.
SgII-HA was detected using a monoclonal anti-HA antibody and a secondary
10 nm gold-conjugated goat anti-mouse antibody. Panels a and b, newly
formed granules are indicated by the arrowheads. Scale bars, a, 1 m; b, 200
nm. Panels c and d, detailed structure of SgII-containing vesicles. Scale bars,
100 nm. B and C,buoyant density of dense core secretory granules fromPC12
andA35C-S7. Postnuclear supernatants fromamixedpopulationof PC12 and
A35C-S7 cells were subjected to a sucrose density gradient fractionation.
B, immunoblots of CgB (from PC12) and SgII-HA (from A35C-S7) distribution
across the sucrose density gradient. C, quantification of CgB and SgII-HA
amounts in the gradient fractions from B. Values are given as the percent
maximum of either CgB or SgII-HA signal in the gradient fractions.
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pathway for the formation of CgA-containing DCGs in PC12
cells (37). Chronic exposure (22 h) of SgII-GFP-expressing
PC12 cells to a low dose (10 nM) of the selective V-ATPase
inhibitor BafA1 resulted in a reduced number of DCGs positive
for SgII-GFP (supplemental Fig. S2D), which underscores the
importance of V-ATPase-mediated acidification of late com-
partments of the secretory pathway for granulogenesis. Thus,
we questioned whether the SgII-mediated biogenesis of secre-
tory vesicles would also require functional V-ATPases in A35C
cells, and we assessed the effect of chronic exposure of trans-
fected A35C cells to BafA1 (Fig. 7, A and B). Although control
(mock-treated) A35C cells showed an average fluorescent ves-
icle density (number of green punctae/m2 of cell body) of
0.15  0.02, that of A35C cells exposed to BafA1 was down to
0.09 0.01, corresponding to an40% decrease in vesicle den-
sity (p	 0.05, t test; Fig. 7A). In the same conditions (Fig. 7B),
exposure of SgII-EAP-expressing A35C cells to BafA1 resulted
in an20% reduction of regulated, A23187-evoked secretion of
FIGURE 6.Mobility of secretory vesicles is comparable in A35C expressing SgII-GFP cells and wild-type PC12 cells. A, TIRFM image of a characteristic
SgII-GFP-containing granule in a transfected A35C cell. The granule trajectory in the xy plane (green line) over a period of 300 s was used to generate x and y
coordinates and calculate theMSDanddiffusion coefficient values. Scale bar, 100nm. B, x and y coordinates extracted fromA as a function of time.C,MSD from
the origin as a function of time obtained from B. D,mobility of SgII-containing granules in SgII-GFP-expressing A35C versus PC12 cells. Diffusion coefficients
(Dxy) values from 171 vesicles in 12 A35C cells and 141 vesicles in 12 PC12 cells were ranked according to histogram intervals and compared using a
Mann-Whitney two-tail test.
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the chimera as compared with control cells (p	 0.01; Fig. 7B).
Therefore, V-ATPase acidification of the engendered secretory
pathway in A35C cells is required for the DCG forming activity
of SgII.
Regulation of Secretory Granule Intravesicular pH (pHves) in
LivingA35CCells—Wenext aimed at investigating the status of
pHves in SgII-GFP-containing granules in A35C cells (Fig. 7, C
and D). As anticipated, titration of SgII-GFP fluorescence in
cella revealed strong sensitivity to pH with an apparent pKa of
6.34  0.04 and a Hill coefficient of 0.9  0.03 (Fig. 7C). Con-
sistent with the known acidic pH of chromaffin granules (55),
the pHves of PC12 was 5.78  0.06 (Fig. 7D). A similar acidic
pHves was observed in A35C (5.72  0.07; Fig. 7D), suggesting
functional V-ATPases in the newly formed SgII-containing
granules. To test this hypothesis,
transfected A35C and PC12 cells
were further exposed to an acute
dose of BafA1 (100 nM), and single
cell fluorescence response was
monitored over time. As shown in
Fig. 7D, exposure to BafA1 pro-
voked a rapid alkalinization of SgII-
containing granules in both PC12
and A35C cells, ultimately leading
to the equilibration of pHves with
cytoplasmic pH values (PC12,
7.53 0.13; A35C, 7.11 0.07; Fig.
7D). Kinetics of such alkalinization
were similar between PC12 and
A35C cells (p 0.05, Mann-Whit-
ney two-tail test; Fig. 7D), con-
firming that the SgII-containing
granules in A35C cells contain
functional V-ATPases maintain-
ing the acidic luminal pH charac-
teristic of bona fide DCGs.
Plasma Membrane Depolariza-
tion Induces Alkalinization of Secre-
tory Granule Core in PC12 and
A35CCells—In PC12 cells, depolar-
ization of the plasma membrane
results in a rapid, calcium-depen-
dent alkalinization of the DCG core
prior to exocytosis (56). We thus
questioned whether this phenome-
non could be observed inA35C cells
as well (Fig. 8). As expected, super-
fusion of PC12 cells expressing SgII-
GFPwith 50mMKCl induced an ini-
tial rapid fluorescence increase
(110%; Fig. 8A), corresponding to
vesicle alkalinization before exocy-
tosis (56) followed by a slow fluores-
cence decrease, indicative of pep-
tide release by exocytosis (Fig. 8A)
(56). Accordingly, when botulinum
C1 light chain (L-BoNT/C1), a
blocker of late soluble NSF attach-
ment protein receptor-mediated steps in exocytosis (10), was
co-expressedwith SgII-GFP, the initial alkalinization phasewas
followed by a sustained increase in fluorescence (200%, Fig.
8A), indicating the retention of SgII-GFP inside the granules
due to impaired formation of the exocytotic pore. However, the
absence of Ca2 outside (EGTA) or inside (BAPTA/AM)
PC12 cells failed to prevent the rapid alkalinization phase in our
conditions (Fig. 8A) (56). No fluorescence variations were
observedwhen vehiclewas added instead of KCl (Fig. 8A), dem-
onstrating the specificity of the response to the depolarization
process.
When A35C cells expressing SgII-GFP were subjected to
membrane depolarization with 50 mM KCl, SgII-GFP fluores-
cence exhibited the same initial rapid increase (110%; Fig. 8) as
FIGURE7.Effectsof thevacuolarH-V-ATPase inhibitorBafA1onthegranule formingactivityofSgII and
the regulation of pHves in SgII-expressing A35C cells. A, subcellular distribution of SgII-GFP in A35C cells
treated with BafA1. A35C transfected with SgII-GFP and exposed (22 h) tomock (DMSO) or BafA1 (10 nM) were
analyzedbydeconvolutionmicroscopy. Shownare representative three-dimensional (3D) imagesor xy section
(0.2 m) views. Nuclei were visualized with Hoechst 33342 (blue). Scale bars, 5 m. *, p 	 0.05, t test.
B, secretagogue-evoked release of SgII-EAP after BafA1 treatment. A35C cells transfected with SgII-EAP and
exposed (22 h) to mock (DMSO) or BafA1 (10 nm) were subjected to a 30-min exposure to DMEM alone () or
DMEM supplemented with 5 M A23187 () and assayed for EAP secretion. The release of EAP is expressed
relative to enzymatic activity released in the absence of secretagogue. Values are given as the mean S.E. of
three independent experiments, eachdone in triplicate. **,p	 0.005; ***,p	 0.001, as comparedwith control,
analysis of variance with Bonferroni’s post hoc test. C, representative pH titration curve of SgII-GFP fluores-
cence. a.u., arbitrary units. D, effect of BafA1 on pHves in A35C versus PC12 cells. PC12 and A35C cells (n 5)
expressing SgII-GFP were exposed to 100 nM BafA1. Fluorescence was monitored every 30 s over a 20-min
period, and algebraic conversion of GFP fluorescence to pH values was obtained as described under “Experi-
mental Procedures,” using the pH titration curve shown in C. Values are given as themean S.E. Kinetics of pH
increase were compared using a Mann-Whitney two-tail test.
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in PC12 cells (Fig. 8A). However, it was followed by a slow and
sustained fluorescence rise (140%; Fig. 8B), similar to that of
L-BoNT/C1 co-expressing PC12 (Fig. 8A) or A35C (Fig. 8B),
and therefore reminiscent of impaired formation of the fusion
pore. Although the initial alkalinization phase in A35C was
Ca2-independent (Fig. 8B) as in
PC12 cells (Fig. 8A), Ca2 depletion
in A35C cells abolished the second
phase of the response (Fig. 8B).
DISCUSSION
Overview—In this study, we
aimed at characterizing the role of
SgII in the biogenesis of DCGs of
sympathoadrenal chromaffin cells.
Although this secretory protein has
been extensively used as amarker of
the regulated secretory pathway (53,
57, 58), its function in the formation
of DCGs has not been carefully
investigated, and so far it remains
elusive (19, 22). By analyzing the
consequences of SgII down-regula-
tion in the neuroendocrine PC12
cell line, and its ability to rescue a
regulated secretory pathway in the
secretory-deficient PC12 variant
A35C, we demonstrate the impor-
tance of SgII for DCG biogenesis in
neuroendocrine cells and character-
ize fundamental features of SgII-
mediated granulogenesis.
SgII as Necessary Factor in the
Formation of DCGs in PC12 Cells—
Unlike results from CgA knock-
out mice reporting concomitant
changes in CgB and SgII expression
(14, 15, 38), the down-regulation of
SgII expression in isolated PC12
cells did not alter the expression lev-
els of CgA and CgB (Fig. 1). In line
with studies addressing CgA- or
CgB-mediated granulogenesis in
model cell lines (11, 12, 47), our
results emphasize the necessity of in
cella analyses to assess the direct
role of granins in the regulation of
DCG formation. We found a dis-
proportion between the degree of
silencing of SgII expression and
the decreased number of DCGs in
PC12 cells (80% versus 40%;
Fig. 1); such disproportion has
been reported for CgA and CgB
silencing effects as well (10–12).
This substantiates the concept of
granulogenic redundancy, which
may now be broadened to the
three major granin family members.
What is the catecholamine metabolism status in PC12 cells
lacking SgII? Uptake, storage, and exocytotic release of cat-
echolamines are impaired in CgA-deficient mice (14, 38, 59),
perhaps because of the combined absence of catecholamine
FIGURE 8. KCl depolarization induces alkalinization of SgII-GFP-containing granules in PC12 and
A35C cells. Kinetics of fluorescence changes following KCl depolarization in PC12 cells (A) or A35C cells (B)
expressing SgII-GFP alone or together with botulinum neurotoxin C1 light chain (L-BoNT/C1). Cells were
preincubated for 10 min in either a calcium-containing buffer (CaB), a calcium-depleted buffer (CaB),
or a calcium-depleted buffer containing 50 mM of BAPTA/AM (CaB  BAPTA/AM). Whole cell fluores-
cence was continuously monitored (500-ms acquisition frames) over a 20-min period. Superfusion of 50
mM KCl (KCl) or H2O (vehicle) was performed at the indicated time (black arrow). Changes in fluorescence
are expressed as a percentage of the fluorescence present in the cell before superfusion. Measurements
were done in triplicate for each cell type, in at least three independent experiments. Shown are the
kinetics of one typical transfected cell.
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binding/concentration properties of CgA (60) and the lower
catecholamine affinity of the remaining cargo proteins, includ-
ing SgII (38). Although additional experiments are required to
further characterize the relationships between SgII and cate-
cholaminemetabolism, its necessary role for DCG formation in
sympathochromaffin cells described in this study creates a con-
vincing mechanistic link for the previously observed associa-
tion between quantitative genetic variation at the SCG2 locus
and human hypertension (2).
Prototype secretory proteins with a trafficking fate depen-
dent on the presence/absence of a regulated secretory pathway
(e.g. constitutively secreted or mis-trafficked to the lysosomal
pathway in secretory-deficient variants) include human growth
hormone, the bovine pro-hormone pro-opiomelanocortin, and
carboxypeptidase H (10, 12, 27, 61). Here, we used NPY, routed
to the mitochondria in non-neuroendocrine and secretory-de-
ficient neuroendocrine cells (42–45), as a prototype secretory
protein. The substantial re-localization of NPY-GFP (25) in
SgII-depleted PC12 cells and rescued A35C cells (Fig. 2) clearly
emphasizes the chaperone function of SgII for NPY trafficking
during DCG biogenesis. Of note, the initial characterization of
the A35C cell line reported a then inexplicable mitochondrial
morphology variation (27) that might now be linked to the
mitochondrial re-localization of endogenous NPY.
SgII Can Rescue the Formation of DCGs and a Regulated
Secretory Activity in A35C Cells—Taking our cue from the
experimental paradigm developed in our earlier studies on SgII
trafficking (23) and CgA-mediated granulogenesis in sympatho-
adrenal cells (10), we assessed the ability of SgII to rescue the for-
mation of functional DCGs (47, 62) in the secretory-deficient
PC12 variant A35C.We conclude from our results (Figs. 3 and 5)
that the morphological parameters defining a DCG (63) are met
when SgII is expressed in A35C cells. Similar outcomes are
obtaineduponexpressionofCgA in secretory-deficient endocrine
cells lines (10, 12). However, expression of CgA, CgB, or SgII in
non-neuroendocrine cells consistently generates larger vesicular
structures than PC12DCGs (11, 17, 19). Secretory-deficient PC12
variantsmay therefore be higher fidelity cellularmodels to under-
stand the neurosecretion competence (46, 64).
A sine quanone characteristic of functional secretory granule
is the ability to store and release its cargo upon stimulation (10,
12, 19, 46, 62). Our complementary secretion approaches
clearly establish the exocytotic release of SgII triggered by expo-
sure of rescued A35C cells to secretory stimuli (Fig. 4) and pro-
vide evidence for the efficient retention of SgII under basal con-
ditions both in A35C and COS-7 cells. However, our kinetic
results onDCG alkalinization in response to plasmamembrane
depolarization (Fig. 8) suggest that a less efficient exocytotic
process leads to intracellular accumulation of secretion-incom-
petent granules, perhaps due to limited recovery of soluble NSF
attachment protein receptors deficiencies in A35C cells.
Accordingly, we noticed amodest exocytosis frequency of SgII-
GFP in transfected A35C measured by TIRFM (Fig. 3E), as
compared with that of Vamp-GFP or NPY fusion proteins in
bovine chromaffin or PC12 cells (41, 65),5 as well as a system-
atically lower steady-state regulated release of SgII in A35C as
compared with PC12 cells (Fig. 3B and supplemental Fig. S2C)
(23). Also, the average density of SgII-GFP-containing granules
in transfected A35C cells was lower than that of transfected
PC12 cells (0.15  0.09 punctae per m2 versus 0.91  0.07
punctae per m2, see Fig. 7A and supplemental Fig. S2B). A
similar conclusionmay be drawn from our CgA studies (10, 37)
and from CgB- or SgII-regulated secretion in non-neuroendo-
crine cell lines (11, 19). Despite the moderate efficiency of SgII
to establish an otherwise bona fide neurosecretory phenotype,
the strength of the mutant A35C cell model lies in its ability to
implement a minimalistic yet robust approach to study basic
mechanisms that underlie the granulogenic role of SgI in a cel-
lular system of neuroendocrine origin in the absence of a puta-
tive compensatory effect from other granins.
Most of the intrinsic properties of SgII-containing DCGs in
living A35C cells analyzed in this study point toward a substan-
tial homology with genuine SgII-GFP-containing DCGs in
PC12 cells (Figs. 6–8) (35, 56, 66). Rescued A35C cells may
therefore contain theminimal machinery necessary for the for-
mation ofmatureDCGs via a typical and functionalmaturation
process (53), including acidification of immature secretory
granule core through the proton pump V-ATPase (55), trans-
port toward the plasma membrane (67), and transduction of a
signal for intragranular pH rise in response to plasma mem-
brane depolarization. A chromaffin granule membrane
Na/H antiporter activity (68) may contribute to changes in
granule core cation concentrations during stimulation (69), as
well as a Ca2-independent, high conductance K-selective
granule membrane channel (70). Further experiments, e.g. pro-
teomic analyses, will be needed to specify the exact composition
of SgII-containing DCGs in rescued A35C cells and further dis-
sect the proteinmachineries present in newly formed secretory
granules.
Granulogenic Role of SgII, Mechanism, Hypothesis, and
Future Directions—What are the mechanisms underlying the
granulogenic function of SgII? We propose that SgII acts
through aggregation to initiate the physical driving force
required for vesicle budding at the TGN. Granins undergo
acidic pH- and Ca2-dependent aggregation in vitro (6, 7, 60)
and in cella (5), and predicted coiled-coil secondary conforma-
tions may enable their very dense packaging within secretory
granules (59). Sorting of SgII into the regulated secretory path-
way of PC12 requires an acidic environment (57) and relies on a
saturable mechanism at the TGN (23). A V-ATPase-mediated
acidification of the secretory pathway is known to be necessary
forDCGbiogenesis in several neuroendocrine cell types (37, 71,
72), and expression of aggregation-competent regulated cargo
proteins is sufficient for granule-like formation in non-neu-
roendocrine cells (11, 12, 17, 19, 73). Here, using the secretory-
deficient A35C cells, we specifically establish the V-ATPase-
dependent granule forming activity of SgII (Fig. 7), sustaining
the hypothesis that SgII aggregates pioneer the formation of
secretory granules.
Because inhibition of the V-ATPase activity partially abol-
ishes SgII granulogenic activity in rescued A35C cells (Fig. 7),
additional trans-determinants may contribute to DCG forma-
tion at the TGN. For instance, SgII, CgA, and CgB are known to5 M. Courel, D. T. O’Connor, and L. Taupenot, unpublished results.
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interact with vesicle membranes at acidic pH (7, 74, 75), and
specific binding partners for CgA at the TGN have been iden-
tified, including the granin family member SgIII (76–79) and
the Golgi-resident proteins of the stathmin family SCLIP and
SCG10 (61). Interaction between CgA and SgIII involves the
amino-terminal -helical structure CgA-(48–111) (78), which
contains both a necessary sorting domain in PC12 cells (28) and
a granulogenic determinant in A35C and COS-1 cells (10, 18).
SgIII interacts in cellawith SgII in pituitary cells (80) but not in
PC12 (78). Down-regulation of SCLIP expression alters the
trafficking of SgII in PC12 (61), although a direct interaction
between SgII and SCLIP has yet to be determined. Considering
the secondary structure findings pertaining to CgA (10, 18, 28),
we propose that the two small -helical sorting domains of SgII
(23) will be of interest for both cis- and trans-determinant
mechanisms mediating SgII granulogenic activity.
The granulogenic function of SgII might result as well from a
more widespread, overall regulatory effect of the granin.
Indeed, the characterization of secretory-deficient variants of
PC12 cells points to alterations in transcriptional control of the
regulated secretory pathway (46, 64, 81), and a post-transla-
tional regulatory mechanism mediated by the protease inhibi-
tor protease Nexin-1 is proposed to account for the granulo-
genic role of CgA in pituitary 6T3 cells (12, 82, 83). How
silencing of SgII in PC12 cells affects the expression of other
crucial components of the DCG and whether such proteins are
synthesized de novo by rescued A35C cells remain to be discov-
ered. CgB may be present in the nuclei of chromaffin cells and
rat cardiomyocytes where it could have a regulatory effect on
gene expression (84, 85). Of note, SgII reportedly co-localizes
with CgB in the nuclei of PC12 cells (86), and the SgII-derived
peptidemanserin has been detected as well in nuclei of rat duo-
denal villus cells (87).
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